• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经 NTBC 治疗的 I 型遗传性酪氨酸血症患者角膜晶体的共焦显微镜检查。

Confocal microscopy of corneal crystals in a patient with hereditary tyrosinemia type I, treated with NTBC.

机构信息

Department of Ophthalmology, Ghent University Hospital, Ghent, Belgium.

出版信息

Cornea. 2013 Jan;32(1):91-4. doi: 10.1097/ICO.0b013e318243e474.

DOI:10.1097/ICO.0b013e318243e474
PMID:22495034
Abstract

PURPOSE

To describe the confocal microscopic findings in a patient with hereditary tyrosinemia type I (HT-I) treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) who developed corneal crystals.

METHODS

In this case study, we describe the confocal microscopic findings in a boy, who was diagnosed with HT-I at the age of 4 months. At 16 years of age, he developed painful corneal lesions in both eyes. On slit-lamp examination, whorl-like branching epithelial corneal lesions were found, staining faintly with fluorescein. His NTBC treatment was stopped and reintroduced at a lower dose after 1 month. The lesions clearly regressed, leaving only mild residual epithelial scarring, without fluorescein staining and without pain. Confocal microscopy was performed in the acute painful stage and in the asymptomatic convalescent stage 5 months later.

RESULTS

Confocal microscopy confirmed the presence of slender birefringent spiky crystals in the very superficial corneal epithelium. In the asymptomatic convalescent phase, the crystals clearly persisted on confocal microscopy, although they were barely visible on slit-lamp examination.

CONCLUSIONS

This is the first in vivo demonstration by confocal microscopy of corneal crystals present in a patient with proven type I tyrosinemia, under NTBC treatment.

摘要

目的

描述接受 2-(2-硝基-4-三氟甲基苯甲酰基)-1,3-环己二酮(NTBC)治疗的 I 型遗传性酪氨酸血症(HT-I)患者出现角膜晶体的共焦显微镜检查结果。

方法

在本病例研究中,我们描述了一名男孩的共焦显微镜检查结果,他在 4 个月大时被诊断出患有 HT-I。16 岁时,他的双眼出现疼痛性角膜病变。在裂隙灯检查下,发现涡旋状分支状上皮角膜病变,荧光素染色呈弱阳性。他的 NTBC 治疗在 1 个月后停止,并以较低剂量重新开始。病变明显消退,仅留下轻微的残留上皮瘢痕,无荧光素染色,无疼痛。在急性疼痛阶段和 5 个月后的无症状恢复期进行了共焦显微镜检查。

结果

共焦显微镜检查证实,非常浅层的角膜上皮中存在细长的双折射刺状晶体。在无症状的恢复期,晶体在共焦显微镜下清晰可见,尽管在裂隙灯检查下几乎看不见。

结论

这是首例通过共焦显微镜对接受 NTBC 治疗的 I 型酪氨酸血症患者的角膜晶体进行的体内证明。

相似文献

1
Confocal microscopy of corneal crystals in a patient with hereditary tyrosinemia type I, treated with NTBC.经 NTBC 治疗的 I 型遗传性酪氨酸血症患者角膜晶体的共焦显微镜检查。
Cornea. 2013 Jan;32(1):91-4. doi: 10.1097/ICO.0b013e318243e474.
2
Corneal opacities associated with NTBC treatment.与NTBC治疗相关的角膜混浊
Am J Ophthalmol. 2002 Aug;134(2):266-8. doi: 10.1016/s0002-9394(02)01532-5.
3
Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.接受NTBC治疗的I型遗传性酪氨酸血症患者怀孕。
J Pediatr Gastroenterol Nutr. 2015 Jan;60(1):e5-7. doi: 10.1097/MPG.0b013e3182a27463.
4
In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.简而言之:用于遗传性酪氨酸血症的尼替西农(奥法迪恩)。
Med Lett Drugs Ther. 2016 Oct 10;58(1505):e132.
5
[Evolution of a case of tyrosinemia type I treated with NTBC].[1例接受NTBC治疗的I型酪氨酸血症病例的演变]
An Esp Pediatr. 2001 Mar;54(3):305-9.
6
Tyrosinemia I, a model for human diseases mediated by 2-oxoacid-utilizing dioxygenases: hepatotoxin suppression by NTBC does not normalize hepatic collagen metabolism.酪氨酸血症I型,一种由利用2-氧代酸的双加氧酶介导的人类疾病模型:NTBC对肝毒素的抑制作用并未使肝脏胶原代谢正常化。
J Pediatr Gastroenterol Nutr. 2002 Jul;35(1):73-8. doi: 10.1097/00005176-200207000-00016.
7
Discontinuation of NTBC after liver transplantation in tyrosinemia type 1.1型酪氨酸血症患者肝移植后停用尼替西农的情况
Pediatr Int. 2018 Nov;60(11):1039-1041. doi: 10.1111/ped.13697. Epub 2018 Oct 30.
8
The role of nitisinone in tyrosine pathway disorders.尼替西农在酪氨酸途径疾病中的作用。
Curr Rheumatol Rep. 2014 Nov;16(11):457. doi: 10.1007/s11926-014-0457-0.
9
From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.从毒理学问题到治疗用途:2-(2-硝基-4-三氟甲基苯甲酰基)-1,3-环己二酮(NTBC)作用机制的发现、毒理学及药物研发
J Inherit Metab Dis. 1998 Aug;21(5):498-506. doi: 10.1023/a:1005458703363.
10
In vivo confocal microscopic features of corneal pseudodendritic lesions in tyrosinemia type II.II型酪氨酸血症中角膜假树枝状病变的体内共聚焦显微镜特征
Cornea. 2014 Oct;33(10):1106-8. doi: 10.1097/ICO.0000000000000226.

引用本文的文献

1
Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.1 型酪氨酸血症的药物治疗的长期结果和实际考虑
Paediatr Drugs. 2019 Dec;21(6):413-426. doi: 10.1007/s40272-019-00364-4.
2
Asymptomatic Corneal Keratopathy Secondary to Hypertyrosinaemia Following Low Dose Nitisinone and a Literature Review of Tyrosine Keratopathy in Alkaptonuria.低剂量尼替西农治疗后高酪氨酸血症继发的无症状性角膜病变及黑尿病中酪氨酸角膜病变的文献综述
JIMD Rep. 2018;40:31-37. doi: 10.1007/8904_2017_62. Epub 2017 Sep 24.
3
Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.
I 型酪氨酸血症的诊断和治疗:美国和加拿大共识小组的回顾和建议。
Genet Med. 2017 Dec;19(12). doi: 10.1038/gim.2017.101. Epub 2017 Aug 3.
4
Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1.1型遗传性酪氨酸血症的富马酰乙酰乙酸水解酶基因敲除兔模型
J Biol Chem. 2017 Mar 17;292(11):4755-4763. doi: 10.1074/jbc.M116.764787. Epub 2017 Jan 4.
5
Reversible keratopathy due to hypertyrosinaemia following intermittent low-dose nitisinone in alkaptonuria: a case report.间歇性低剂量尼替西农治疗黑尿症后因高酪氨酸血症导致的可逆性角膜病变:一例报告
JIMD Rep. 2014;17:1-6. doi: 10.1007/8904_2014_307. Epub 2014 Jul 6.